Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Unresectable CRLM
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
To date no prospective trials have been completed that demonstrated whether RFA is an
effective adjunct to systemic chemotherapy (target therapy) with respect to advantages in
overall survival compared with chemotherapy (target therapy) alone. The primary objective of
this trial is to determine overall survival for patients with colorectal cancer liver
metastasis are treated with radiofrequency ablation plus chemotherapy ± target therapy,
compared to chemotherapy ± target therapy only.